Trends in antifungal use and epidemiology of nosocomial yeast infections in a University Hospital

Journal of Clinical Microbiology

Volumn 37, Issue 3, 1999, Pages 531-537

  Berrouane, Yasmina F ^a,e   Herwaldt, Loreen A ^a,b,c,d   Pfaller, Michael A ^a  

^a Department of Internal Medicine ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; KETOCONAZOLE;

ARTICLE; BONE MARROW TRANSPLANTATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CATHETER INFECTION; DRUG USE; FUNGEMIA; GASTROINTESTINAL SURGERY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MYCOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION;

CANDIDA ALBICANS; CANDIDA GLABRATA; TRIXIS;

EID: 0033034277     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.3.531-537.1999     Document Type: Article

References (39)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128.
2. Aucott, J. N., J. Fayen, H. Grossnicklas, A. Morrissey, M. M. Lederman, and R. A. Salata. 1990. Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev. Infect. Dis. 12:406-411.
3. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 91(Suppl. 3B):86S-89S.
4. Beck-Sague, C. M., W. R. Jarvis, and The National Nosocomial Infections Surveillance System. 1991. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980 to 1990. J. Infect. Dis. 167:1247-1251.
5. Berrouane, Y. F., R. J. Hollis, and M. A. Pfaller. 1996. Strain variation among and antifungal susceptibilities of isolates of Candida krusei. J. Clin. Microbiol. 34:1856-1858.
6. Bodey, G. P. 1992. Azole antifungal agents. Clin. Infect. Dis. 14(Suppl. 1):S161-S169.
7. Borg-Von Zepelin, M., H. Eiffert, M. Kann, and R. Rüchel. 1993. Changes in the spectrum of fungal isolates: results from clinical specimens gathered in 1987/88 compared with those in 1991/92 in the University Hospital Göttingen, Germany. Mycoses 36:247-253.
8. Broderick, A., M. Man, M. D. Nettleman, S. A. Streed, and R. P. Wenzel. 1990. Nosocomial infections: validation of surveillance and computer modeling to identify patients at risk. Am. J. Epidemiol. 131:734-742.
9. Bross, J., G. H. Talbot, G. Maislin, S. Hurwitz, and B. L. Strom. 1989. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am. J. Med. 87:614-620.
10. Doebbeling, B. N., R. J. Hollis, H. D. Isenberg, R. P. Wenzel, and M. A. Pfaller. 1991. Restriction fragment analysis of a Candida tropicalis outbreak of sternal wound infections. J. Clin. Microbiol. 29:1268-1270.
11. Fraser, V., M. Jones, J. Dunkel, S. Storfer, G. Medoff, and W. C. Dunagan. 1992. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15:414-421.
12. Fridkin, S. K., and W. R. Jarvis. 1996. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 9:499-511.
13. Goldman, M., J. C. Pottage, and D. C. Weaver. 1993. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine (Baltimore) 72:143-150.
14. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, and D. J. Friedman. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
15. Grasela, T. H., S. D. Goodwin, M. T. Pasko, C. A. Walawander, and M. A. Raebel. 1994. Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole. Ann. Pharmacother. 28:252-260.
16. Grasela, T. H., M. T. Pasko, S. D. Goodwin, C. A. Walawander, N. Blackwelder, and R. J. Bruder-Holt. 1994. Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole. Ann. Pharmacother. 28:261-270.
17. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
18. Jarvis, W. R., J. R. Edwards, D. H. Culver, J. M. Hughes, T. Horan, T. G. Emori, S. Banerjee, J. Tolson, T. Henderson, and R. P. Gaynes. 1991. Nosocomial infection rates in adults and pediatric intensive care units. Am. J. Med. 91:185S-191S.
19. Karabinis, A., C. Hill, B. Leclercq, C. Tancrede, D. Baume, and A. Andremont. 1988. Risk factors for candidemia in cancer patients: a case-control study. J. Clin. Microbiol. 26:429-432.
20. Levine, J., R. K. Dykoski, and E. N. Janoff. 1995. Candida-associated diarrhea: a syndrome in search of credibility. Clin. Infect. Dis. 21:881-886.
21. Meunier-Carpentier, F., T. E. Kiehn, and D. Armstrong. 1981. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am. J. Med. 71:363-370.
22. Nguyen, M. H., J. E. Peacock, A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
23. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
24. Pfaller, M. A., R. N. Jones, S. A. Messer, M. B. Edmond, R. P. Wenzel, and The SCOPE Participant Group. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. 30:121-129.
25. Pfaller, M. A., R. N. Jones, S. A. Messer, M. B. Edmond, and R. P. Wenzel. 1997. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. 31:327-332.
26. Pfaller, M. A., S. A. Messer, A. Houston, M. S. Rangel-Frausto, T. Wiblin, H. M. Blumberg, J. E. Edwards, W. Jarvis, M. A. Martin, H. C. Neu, L. Saiman, J. E. Patterson, J. C. Dibb, C. M. Roldan, M. G. Rindaldi, and R. P. Wenzel. 1998. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn. Microbiol. Infect. Dis 31:289-296.
27. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. Frame, W. He, C. van der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. Waskin, T. M. Hooton, N. Hyslop, S. A. Spector, S. A. Bozzette, and The NIAID AIDS Clinical Trials Group. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
28. Price, M. F., M. T. LaRocco, and L. O. Gentry. 1994. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemother. 38:1422-1424.
29. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
30. Richardson, K., K. Cooper, M. S. Marriott, M. H. Tarbit, P. F. Troke, and P. J. Whittle. 1990. Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis. 12(Suppl. 3):S267-S271.
31. Strausbaugh, L. J., D. L. Sewell, T. T. Ward, M. A. Pfaller, T. Heitzman, and R. Tjoelker. 1994. High frequency of yeast carriage on hands of hospital personnel. J. Clin. Microbiol. 32:2299-2300.
32. U.S. Department of Health, Education, and Welfare. 1972. Outline for surveillance and control of nosocomial infections. Centers for Disease Control, Atlanta, Ga.
33. Vazquez, J. A., V. Sanchez, C. Dmuchowski, L. M. Dembry, J. D. Sobel, and M. J. Zervos. 1993. Nosocomial acquisition of Candida albicans: an epidemiologic study. J. Infect. Dis. 168:195-201.
34. Voss, A., M. A. Pfaller, R. J. Hollis, J. Rhine-Calberg, and B. N. Doebbeling. 1995. Investigation of Candida albicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods. J. Clin. Microbiol. 33:576-580.
35. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
36. Wingard, J. R. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.
37. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1315.
38. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
39. Zerva, L., R. J. Hollis, and M. A. Pfaller. 1996. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J. Clin. Microbiol. 34:3031-3034.